Angiotensin receptor-1 antagonist eprosartan in patients with mild to moderate arterial hypertension

Aim. To study clinical effectiveness of eprosartan mesylate in treating patients with Stage I-II arterial hypertension (AH). Material and methods. In total, 28 patients (20 males, 8 females) with Stage I-II AH, risk 2-3, aged 28-56 years (mean age 40.0±1.3), were examined. All participants received eprosartan monotherapy (600 mg once per day) for 8 weeks. At baseline and 8 weeks later, 24-hour ECG and blood pressure (BP) monitoring, stress echocardiography with counting test, cognitive functions and quality of life (SF-36 Questionnaire) assessments were performed. Results. Eprosartan monotherapy was associated with moderate antihypertensive and sympatholytic effects, decreased diastolic dysfunction during psycho-emotional stress, and no negative influence on cognitive processes. Conclusion. Eprosartan could be used for treating patients with Stage I-II essential AH, whose professional activity demands intact superior neuro-psychic functions.